Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Besarab

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Transplantation Proceedings|February 1, 1991
Evidence against chronic progressive cyclosporine nephrotoxicityC S Ben-Maimon, J F Burke, A Besarab, et al.
Kidney International|May 7, 1999
Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysisA Gupta, N B Amin, A Besarab, et al.
International Journal of Dermatology|December 11, 1991
Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritusG C Francos, Y C Kauh, S D Gittlen, et al.
JAMA|June 28, 1976
Reversible renal failure following bilateral renal artery occlusive disease. Clinical features, pathology, and the role of surgical revascularizationA Besarab, R S Brown, N T Rubin, et al.
Journal of the American Society of Nephrology : JASN|March 1, 1992
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationA Besarab, K K Flaharty, A J Erslev, et al.
Journal of the American Society of Nephrology : JASN|April 4, 1998
Simplified measurement of intra-access pressureA Besarab, S Frinak, R A Sherman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 1985
Dialysis-induced hypoxemia: membrane dependent and membrane independent causesG C Francos, A Besarab, J F Burke, et al.
The New England Journal of Medicine|August 27, 1998
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinA Besarab, W K Bolton, J K Browne, et al.
Clinical Nephrology|June 5, 2007
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyR Provenzano, A Besarab, I C Macdougall, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Transplantation Proceedings|February 1, 1991
Evidence against chronic progressive cyclosporine nephrotoxicityC S Ben-Maimon, J F Burke, A Besarab, et al.
Kidney International|May 7, 1999
Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysisA Gupta, N B Amin, A Besarab, et al.
International Journal of Dermatology|December 11, 1991
Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritusG C Francos, Y C Kauh, S D Gittlen, et al.
JAMA|June 28, 1976
Reversible renal failure following bilateral renal artery occlusive disease. Clinical features, pathology, and the role of surgical revascularizationA Besarab, R S Brown, N T Rubin, et al.
Journal of the American Society of Nephrology : JASN|March 1, 1992
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationA Besarab, K K Flaharty, A J Erslev, et al.
Journal of the American Society of Nephrology : JASN|April 4, 1998
Simplified measurement of intra-access pressureA Besarab, S Frinak, R A Sherman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 1985
Dialysis-induced hypoxemia: membrane dependent and membrane independent causesG C Francos, A Besarab, J F Burke, et al.
The New England Journal of Medicine|August 27, 1998
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinA Besarab, W K Bolton, J K Browne, et al.
Clinical Nephrology|June 5, 2007
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyR Provenzano, A Besarab, I C Macdougall, et al.
Pageof 10